跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 129 条关于
“ETV6-NTRK3”
全部
129
临床试验
91
药物
22
机构
0
资讯
16
2个月前
Rare Histological Subtypes of Triple-Negative Breast Cancer: A Comprehensive Review Highlights Diagnostic and Therapeutic Implications
去年
Genomic Testing and Larotrectinib Give New Life to Patient with Rare NTRK Fusion Cancer
6个月前
C-Further Launches First Pediatric Cancer Programs with $40M Budget, Partners with MiNK Therapeutics
10个月前
Geneseeq's PanTRKare™ Receives NMPA Approval as China's First NGS-Based Pan-Solid Tumor Companion Diagnostic for NTRK Gene Fusions
去年
Repotrectinib Recommended for EU Approval in ROS1+ NSCLC and NTRK+ Solid Tumors
去年
Next-Generation TRK Inhibitors Show Promise in Treating NTRK Fusion-Positive Cancers
10个月前
InnoCare's Zurletrectinib Shows 90% Response Rate in Pediatric NTRK-Fusion Solid Tumors
去年
CHMP Recommends Repotrectinib for ROS1+ NSCLC and NTRK+ Solid Tumors in Europe
去年
Larotrectinib Shows High Efficacy in Pediatric Solid Tumors with NTRK Fusion
去年
Avistone's ANS03, a Novel ROS1/NTRK Inhibitor, Receives FDA IND Clearance
第 1 页,共 2 页
上一页
下一页